Cargando…

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy

The increasing number of potent treatments for multiple sclerosis warrants screening for infections. To investigate the prevalence of infections in two independent German patient cohorts with multiple sclerosis/neuromyelitis optica spectrum disorders (NMOSD), we performed a retrospective chart revie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Jonas, Leussink, Verena I., Dehmel, Thomas, Ringelstein, Marius, Goebels, Norbert, Adams, Ortwin, MacKenzie, Colin R., Warnke, Clemens, Feldt, Torsten, Lammerskitten, Anna, Klotz, Luisa, Meuth, Sven, Wiendl, Heinz, Hartung, Hans‐Peter, Aktas, Orhan, Albrecht, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740259/ https://www.ncbi.nlm.nih.gov/pubmed/29296620 http://dx.doi.org/10.1002/acn3.491

Ejemplares similares

Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab
por: Harmel, Jens, et al.
Publicado: (2014)

CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy: Subtle Retinal Changes in Optical Coherence Tomography
por: Ingwersen, Jens, et al.
Publicado: (2021)

EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases
por: von Martial, Sophia, et al.
Publicado: (2019)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis
por: Baetge, Sharon Jean, et al.
Publicado: (2021)

Type O blood group associates with higher anti‐JC polyomavirus antibody levels
por: Frenken, Pia, et al.
Publicado: (2021)

Occipital repetitive transcranial magnetic stimulation does not affect multifocal visual evoked potentials
por: Kolbe, Robert, et al.
Publicado: (2020)

Retinal Neurodegeneration in Wilson’s Disease Revealed by Spectral Domain Optical Coherence Tomography
por: Albrecht, Philipp, et al.
Publicado: (2012)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy
por: Graf, Jonas, et al.
Publicado: (2018)

Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity
por: Sabet, Mercedeh Farhat, et al.
Publicado: (2022)

Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone
por: Krämer, Julia, et al.
Publicado: (2021)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

Optical Coherence Tomography in Parkinsonian Syndromes
por: Albrecht, Philipp, et al.
Publicado: (2012)

Subtle retinal pathology in amyotrophic lateral sclerosis
por: Ringelstein, Marius, et al.
Publicado: (2014)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS
por: Brandt, Alexander U., et al.
Publicado: (2012)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy
por: Jarius, Sven, et al.
Publicado: (2016)

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
por: Ng, Huah Shin, et al.
Publicado: (2022)

Meningitis gone viral: description of the echovirus wave 2013 in Germany
por: Graf, Jonas, et al.
Publicado: (2019)

Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis
por: Breitkopf, Katharina, et al.
Publicado: (2020)

Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2020)

Cryptococcal meningoencephalitis in an IgG(2)-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report
por: Wienemann, Tobias, et al.
Publicado: (2020)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b
por: Ingwersen, Jens, et al.
Publicado: (2015)

Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system
por: Melzer, Nico, et al.
Publicado: (2012)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

COVID-19 and management of neuroimmunological disorders
por: Hartung, Hans-Peter, et al.
Publicado: (2020)

Fingolimod treatment promotes regulatory phenotype and function of B cells
por: Grützke, Berit, et al.
Publicado: (2015)

Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography
por: Oberwahrenbrock, Timm, et al.
Publicado: (2012)

Long‐term adherence and response to botulinum toxin in different indications
por: Lee, John‐Ih, et al.
Publicado: (2020)

Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS
por: Aktas, Orhan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_06rq2arb9du199gt34hiqb76h9